On July 20, Tempus AI fell 8% in pre-market trading, trading at approximately $48.3/share. The decline was triggered by the company's announcement that it will acquire Personalis at $16.25 per share in cash.

The acquisition aims to integrate Personalis's molecular residual disease (MRD) detection technology into Tempus AI's AI-driven precision oncology platform. The company stated that cash consideration will be funded through existing cash reserves and borrowings under its current credit facilities. The deal is expected to enhance cancer recurrence risk assessment and enable earlier intervention.

The market reaction reflects investor concerns over balance sheet impact, particularly as the company recently priced a $400 million convertible senior notes offering in May to repay $307.7 million in outstanding loans. Additional headwinds include the recent termination of its partnership with Biovica International and CEO Eric Lefkofsky's reduction of approximately 126,250 shares in late June. The company is scheduled to report Q2 earnings on July 30.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)